Pfizer Inc. (NYSE:PFE) announced on 4/23/18 that it received a Complete Response Letter (CRL) from the FDA in response to the Biologics License Application for the company’s proposed trastuzumab... read more
Pfizer Inc. (NYSE:PFE) announced on 4/23/18 that it received a Complete Response Letter (CRL) from the FDA in response to the Biologics License Application for the company’s proposed trastuzumab... read more
Pfizer Inc. (NYSE: PFE) today announced that Trumenba (Meningococcal Group B Vaccine) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for active... read more
Fresenius SE ended its pending acquisition of Akorn over a probe that found problems with product development and data. Fresenius issued a statement that said it's decision was based on a number... read more
Bellicum announced on 4/20/18 the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the... read more
Chemoimmunotherapy is a promising technology in the fight against cancer. Researchers at the University of Michigan Rogel Cancer Center have designed a new delivery system – a drug hidden in a... read more